Compare Sanofi SA (SNY) vs United States Oil ETF (USO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs United States Oil ETF — how do they compare? Sanofi SA trades at $40.07 (market cap $95.18B), while United States Oil ETF trades at $148.2 (market cap $1.90B). The key difference: Sanofi SA is far larger — about 50.1× United States Oil ETF's market cap, and Sanofi SA pays a 6.01% dividend while United States Oil ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and United States Oil ETF for 21 Days on average.
| SNY | USO | |
|---|---|---|
Market Cap | $95.18B | $1.90B |
Volume | 2,995,646 | 5,932,922 |
Sector | Health | — |
52-Week High | $52.34 | $161.86 |
52-Week Low | $39.51 | $66.17 |
Typical Hold Time | 94 Days | 21 Days |
Enterprise Value | $114.48B | — |
Dividend Yield | 6.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $40.23, showing minimal daily movement with a 0.07% gain. The stock presents mixed signals with bearish technical indicators but strong fundamental performance, including three consecutive quarterly earnings beats. Recent expansion of the immunology alliance with Regeneron through an $8 billion deal highlights strategic growth initiatives. Valuation metrics show a P/E of 22.14 and P/S of 1.77, while profitability remains solid with a 72.77% gross margin.
SNY offers steady growth potential driven by pipeline expansion and Dupixent momentum, though patent expiration risks loom. Analyst sentiment is cautiously optimistic with 44% buy ratings, but technical weakness and projected 2026 earnings decline present near-term headwinds. The stock represents a balanced opportunity for long-term investors seeking pharmaceutical exposure with manageable risk.
USO is trading at $147.58, up 2.55% with a bullish technical signal supported by moving averages. Recent news highlights Middle East tensions affecting oil supply, with OPEC+ maintaining output targets and G-7 planning strategic oil releases. The stock shows strength above key support levels amid volatile energy market conditions.
The outlook remains cautiously optimistic given geopolitical risks and supply constraints. Investment opportunities include potential price appreciation from supply disruptions, while risks involve oil price volatility and regulatory pressures from climate litigation. Institutional sentiment appears mixed with neutral oscillators suggesting near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About United States Oil ETF
This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →
